GENETIC SIGNATURES LIMITED (GSS)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
GSS - GENETIC SIGNATURES LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.70
18 Apr |
0.000 OPEN $0.70 |
0.000 HIGH $0.70 |
0 LOW $0.70 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | N/A | - 9.4 | xxx |
DPS (cps) | xxx | N/A | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | N/A | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -9.6 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 16.9 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 29.2 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -12.5 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -82.96 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -28.76 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -28.76 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -25.85 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -28.76 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -38.65 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -14.4 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | - |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | - |
Total Debt | xxx | xxx | xxx | xxx | xxx | - |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 16 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.75 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 8.1 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 47.78 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 30 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 6 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
GSS STOCK CHART
FNArena News on GSS
1 |
FNArena Corporate Results Monitor – 26-02-2024Feb 26 2024 - Australia |
2 |
Australian Broker Call *Extra* Edition – Sep 25, 2023Sep 25 2023 - Daily Market Reports |
3 |
Weekly Ratings, Targets, Forecast Changes – 22-09-23Sep 25 2023 - Weekly Reports |
4 |
Australian Broker Call *Extra* Edition – Sep 18, 2023Sep 18 2023 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – May 12, 2023May 12 2023 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
2 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
3 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
4 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
5 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
6 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |